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Abstract: Endoglin is a 180-kDa glycoprotein receptor primarily expressed by the vascular endothelium
and involved in cardiovascular disease and cancer. Heterozygous mutations in the endoglin gene
(ENG) cause hereditary hemorrhagic telangiectasia type 1, a vascular disease that presents with nasal
and gastrointestinal bleeding, skin and mucosa telangiectases, and arteriovenous malformations in
internal organs. A circulating form of endoglin (alias soluble endoglin, sEng), proteolytically released
from the membrane-bound protein, has been observed in several inflammation-related pathological
conditions and appears to contribute to endothelial dysfunction and cancer development through
unknown mechanisms. Membrane-bound endoglin is an auxiliary component of the TGF-β receptor
complex and the extracellular region of endoglin has been shown to interact with types I and II TGF-β
receptors, as well as with BMP9 and BMP10 ligands, both members of the TGF-β family. To search for
novel protein interactors, we screened a microarray containing over 9000 unique human proteins
using recombinant sEng as bait. We find that sEng binds with high affinity, at least, to 22 new proteins.
Among these, we validated the interaction of endoglin with galectin-3, a secreted member of the lectin
family with capacity to bind membrane glycoproteins, and with tripartite motif-containing protein 21
(TRIM21), an E3 ubiquitin-protein ligase. Using human endothelial cells and Chinese hamster ovary
cells, we showed that endoglin co-immunoprecipitates and co-localizes with galectin-3 or TRIM21.
These results open new research avenues on endoglin function and regulation.
Keywords: endothelial cells; endoglin; TGF-β; BMP; HHT; cancer; preeclampsia; TRIM family;
galectin family; protein–protein interactions
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1. Introduction
Endoglin is an auxiliary TGF-β co-receptor predominantly expressed in endothelial cells, which is
involved in vascular development, repair, homeostasis, and disease [1–4]. Heterozygous mutations
in the human ENDOGLIN gene (ENG) cause hereditary hemorrhagic telangiectasia (HHT) type 1,
a vascular disease associated with nasal and gastrointestinal bleeds, telangiectases on skin and mucosa
and arteriovenous malformations in the lung, liver, and brain [4–6]. The key role of endoglin in
the vasculature is also illustrated by the fact that endoglin-KO mice die in utero due to defects in
the vascular system [7]. Endoglin expression is markedly upregulated in proliferating endothelial
cells involved in active angiogenesis, including the solid tumor neovasculature [8,9]. For this reason,
endoglin has become a promising target for the antiangiogenic treatment of cancer [10–12]. Endoglin
is also expressed in cancer cells where it can behave as both a tumor suppressor in prostate, breast,
esophageal, and skin carcinomas [13–16] and a promoter of malignancy in melanoma and Ewing’s
sarcoma [17]. Ectodomain shedding of membrane-bound endoglin may lead to a circulating form of
the protein, also known as soluble endoglin (sEng) [18–20]. Increased levels of sEng have been found in
several vascular-related pathologies, including preeclampsia, a disease of high prevalence in pregnant
women which, if left untreated, can lead to serious and even fatal complications for both mother and
baby [2,18,19,21]. Interestingly, several lines of evidence support a pathogenic role of sEng in the vascular
system, including endothelial dysfunction, antiangiogenic activity, increased vascular permeability,
inflammation-associated leukocyte adhesion and transmigration, and hypertension [18,22–27]. Because
of its key role in vascular pathology, a large number of studies have addressed the structure and
function of endoglin at the molecular level, in order to better understand its mechanism of action.
Endoglin is a 180-kDa disulphide-linked homodimeric type I transmembrane glycoprotein that
contains a large extracellular region (561 amino acids), a single hydrophobic transmembrane domain,
and a short (47 amino acids) cytosolic tail [28,29]. As the extracellular region of endoglin comprises most
(~88%) of the whole protein and is present in circulating sEng, which displays key relevant functions
in vascular biology, several reports have analyzed its structure and interacting protein partners.
Studies of the three-dimensional structure of the ectodomain of endoglin, using single particle electron
microscopy [30], as well as X-ray crystallography [31] have revealed the presence of an N-terminal
orphan region (OR), and a C-terminal bipartite zona pellucida (ZP) module. The conserved ZP
module of endoglin is likely involved in polymerization of extracellular proteins, as reported for
several ZP protein family members [31,32]. In addition, the endoglin ZP module contains an accessible
arginine–glycine aspartic acid (RGD) sequence located in the ZP–N subdomain, which is a consensus
binding motif for integrin recognition [28,31]. Notably, the RGD motif of membrane-bound and soluble
endoglin appears to be actively involved in integrin-mediated cell adhesion, implicating, at least,
α5β1 and αvβ3 integrin family members [24,25,33]. The orphan domain of endoglin is responsible for
the binding with high affinity to members of the TGF-β family, namely BMP9 and BMP10 [31,34,35].
Furthermore, in line with the initially recognized role of endoglin as an essential co-receptor in TGF-β
family signaling [4,36–39], the extracellular region of endoglin can simultaneously bind to BMP9
and the endothelial TGF-β type I receptor ALK1 [31,34,40]. Moreover, the ectodomain of endoglin
specifically interacts with the TGF-β type I receptor ALK5 and with the TGF-β type II receptor [41,42].
Of note, the matrix metalloprotease 14 (MMP14 or MT1-MMP) can bind with and target the extracellular
region of membrane-bound endoglin to release sEng (either alone or in complex with exosomes) upon
proteolytic processing [22,23,42,43]. In addition, in the cancer setting, it has been shown that sEng
associates with the receptor tyrosine kinase Met and antagonizes Met signaling in spindle carcinoma
cells [44]. Nevertheless, the current knowledge about protein interactors of the endoglin ectodomain
does not fully explain the exact molecular mechanisms of action involved in the complex cellular and
pathophysiological roles of endoglin.
In this study, we screened a microarray containing over 9000 unique human proteins
using recombinant sEng as bait. Among the 22 new putative high-affinity interactors identified,
we demonstrated for the first time the specific interaction of endoglin with galectin-3, a secreted
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member of the lectin family with capacity to bind membrane glycoproteins, and with tripartite
motif-containing protein 21 (TRIM21), an E3 ubiquitin-protein ligase. Taken together, this proteomic
study reveals novel avenues on endoglin function and regulation.
2. Materials and Methods
2.1. Cell-free Protein Microarrays
Protein interaction screening was carried out using the ProtoArray human protein Microarray v5.0
(Life Technologies), based on the nucleic acid programmable protein arrays (NAPPA) technology [45].
This microarray contains over 9000 unique human proteins individually purified and arrayed under
native conditions to maximize functionality. Two replicate analyses were hybridized with purified
recombinant human soluble endoglin (sEng; Glu26-Gly586; 1097-EN, R&D Systems). Arrays were
then incubated with a mouse monoclonal antibody (mAb) against human endoglin (clone SN6h,
Dako) and, after washing, with a rabbit antimouse secondary antibody coupled to horseradish
peroxidase [HRP] (P0260, Dako). The specific binding signal was developed using SuperSignalTM West
Pico Plus chemiluminescent substrate (34580, Thermo Fisher Scientific). Arrays were scanned using
an Axon GenePix 4100A microarray reader with the GenePixPro 6.0 program and results analyzed with
Prospector software (Invitrogen). After scanning, chemoluminescence in specific regions on the surface
of arrays were measured and statistically analyzed using Z-scores [46], with the formula: Z = (x − µ)/σ,
where x is the raw value, µ the population mean, and σ the SD for the population. Only those proteins
reaching a Z-score ≥2.0 in two independent protein arrays were considered as candidate bona fide
interacting proteins for further validation analyses.
2.2. Cell Culture
All cell types were incubated routinely at 37 ◦C in a humidified atmosphere with 5% CO2.
Human umbilical vein-derived endothelial cells (HUVECs) were purchased from Lonza and used
at early passages (3–5). HUVECs were grown on 0.2% gelatin (Sigma-Aldrich) pre-coated plates in
endothelial basal medium (EBM2) supplemented with EGM2 SingleQuots (EBM2/EGM2 medium;
Lonza). The Chinese hamster ovary cell line CHO-K1 was cultured in Dulbecco’s modified Eagle’s
medium/Nutrient mixture F-12 medium (DMEM:F12). All cell media were supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Gibco), 2 mM L-glutamine, 100 U/mL penicillin, and 100
µg/mL streptomycin (Gibco), unless otherwise noted.
2.3. Plasmids and Cell Transfections
The following human endoglin expression vectors were used: pDisplay–HA–EngFL (full-length),
pcEXV–HA–EngFL (full-length), pDisplay–HA–EngEC (extracellular region), pDisplay–HA–EngTMEC
(transmembrane and extracellular regions), pDisplay–HA–Mock (empty vector; Ø) and pcEXV–Ø
(empty vector; Ø), all of them previously described [25,37,41]. Some of these vectors encode
endoglin constructs tagged with the human influenza hemagglutinin (HA) epitope, as indicated.
Human TRIM21 or human galectin-3 were overexpressed using the pcDNA3.1–HA–hTRIM21 [47] or
pcDNA3.1–Gal-3 [48], respectively. All plasmids were confirmed by sequencing (Secugen, Madrid).
Transient transfections of CHO-K1 cells with plasmids were carried out using Lipofectamine 2000
(Invitrogen). Cells were analyzed after 48 h of transfection, for protein expression by Western blot.
2.4. Immunoprecipitation Assays
HUVECs or CHO-K1 cells were lysed in lysis buffer (1% NP-40, 0.5 mM NaF, 150 mM NaCl,
50 mM Tris/pH 7.4, and 1 mM phenylmethylsulfonyl fluoride (PMSF)), supplemented with protease
(Roche) and phosphatase (Calbiochem) inhibitors. After 5 min of incubation at 4 ◦C, lysates were
centrifuged at 10,000·g for 5 min and precleared using Protein G magnetic beads (PureProteome-Protein
G magnetic beads, Millipore). Protein concentration of whole-cell extracts was measured using the
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Bradford quantification method (Bio-Rad protein Assay) in a Novaspek Plus Visible Spectrophotometer
(GE Healthcare Life Sciences).
Immunoprecipitations (IPs) for Western blot analysis were carried out using Protein G magnetic
beads incubated with the indicated primary antibodies. For galectin-3/endoglin IP, mouse mAb
anti-galectin-3 (IgG1, clone B2C10, sc-32790, Santa Cruz Biotech) and mouse mAb anti-HA (IgG1, clone
CB051, #TA180128, Origin) were used. For TRIM21/endoglin IP, rabbit mAb anti-TRIM21 (#92043,
Cell Signaling Technology) and mouse mAb anti-endoglin (P4A4, sc-20072, Santa Cruz Biotech) were
used. In all cases, control immunoprecipitations with isotype-matched antibodies (Immunostep)
were carried out. Antibodies were incubated with protein G magnetic beads for 10 min at room
temperature, followed by several washes with PBS. Then, antibody-coupled protein G magnetic
beads were incubated with total cell lysates (~0.5 mg) overnight at 4 ◦C. After washing with PBS,
immunoprecipitates were further analyzed for Western blot analysis.
Co-IPs for proteomic analysis (mass spectrometry) were carried out by incubation of 1 mg of protein
lysates with protein G-coated magnetic beads coupled with either the monoclonal antibody P4A4
anti-endoglin (Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, IA, USA)
or an isotype-matched (IgG2b) control antibody (Immunostep, Salamanca, Spain). An additional
control with protein G magnetic beads in the absence of antibodies was also included. After extensive
washing with PBS, immunoprecipitates were then subjected to mass spectrometry analysis.
2.5. Mass Spectrometry and Data Analysis
Samples from co-IPs were incubated overnight at 4 ◦C on a rotator, washed twice and then
incubated with Laemmli buffer at 95ºC for 5 min. Proteins eluted from each condition (P4A4, IgG2b,
protein G) were analyzed by SDS-PAGE (10% polyacrilamide and 0.1% sodium dodecyl sulphate under
nonreducing and albumin-free conditions, and then stained with colloidal Coomassie Brilliant Blue
(G-250, Sigma). Each lane of gel was divided into small sections, followed by a standard digestion
protocol with trypsin [49,50]. Peptides were trapped onto a C18-A1 ASY-Column (2 cm, ID100 µm,
5 µm) (Thermo Fisher Scientific), and then eluted onto a Biosphere C18 column (75 µm, 16 cm, 3 µm)
(NanoSeparations) and separated using a 110 min gradient min (90 min 0–35% Buffer B, 10 min
35–45% Buffer B, 4 min 45–95% Buffer B, 5 min 95% Buffer B, and 1 min 0% Buffer B) (Buffer A:
0.1% formic acid, 2% acetonitrile; Buffer B: 0.1% formic acid in acetonitrile) at a flow-rate of 200
nL/min on a nanoEasy HPLC (Proxeon) coupled to a nanoelectrospray (Thermo Fisher Scientific).
Mass spectra were acquired on an LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific)
in the positive ion mode. Full-scan MS spectra (m/z 400–2000) were acquired in the Orbitrap at a
resolution of 60,000, and the 15 most intense ions were selected for collision-induced dissociation
(CID) fragmentation in the linear ion trap with a normalized collision energy of 35%. Singly charged
ions and unassigned charge states were rejected. Dynamic exclusion was enabled with an exclusion
duration of 30 s. Mass spectra *.raw files were searched against the human SwissProt 2016_10 database
(20,121 sequence protein entries) using the MASCOT search engine (version 2.3, Matrix Science.
Precursor and fragment mass tolerance were set to 10 ppm and 0.5 Da, respectively, allowing 2 missed
cleavages, N-terminal, carbamidomethylation of cysteines as a fixed modification and methionine
oxidation as a variable modification. Identified peptides were validated using Percolator algorithm
with a q-value threshold of 0.01 [51]. Peptides found in the analysis, which covered ≥2% of a specific
protein region, allowed identifying the proteins present in the sample. These proteins were then
subjected to String-protein database version 11 to analyze possible interactions already described,
between them. The protein identification by nLC–MS/MS was carried out by the Proteomics and
Genomics Facility of Biological Research Center (Centro de Investigaciones Biológicas; CIB-CSIC),
a member of the ProteoRed-ISCIII network.
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2.6. Western Blot Analysis
Total cell lysates or immunoprecipitates were separated by SDS-PAGE on 10% acrylamide
gels under reducing or nonreducing conditions, and resolved proteins were electrotransferred to
polyvinylidene difluoride (PVDF) or nitrocellulose membranes using the semidry system iBlot Gel
transfer (Invitrogen). Then, membranes were blocked with TBS buffer (0.1% Tween, 5% BSA) for 1 h at
room temperature and immunoblotted with primary antibodies, as indicated. For galectin-3/endoglin
IP, anti-galectin-3 (biotinylated polyclonal goat IgG; BAF1154, R&D Systems) and anti-endoglin (rabbit
mAb, clone EPR10145-12, Abcam), antibodies were used. For TRIM21/endoglin IP, anti-TRIM21
(rabbit mAb #92043, Cell Signaling Technology), or anti-HA (mouse mAb, clone CB051, #TA180128,
OriGene) antibodies were used. Loading control antibodies were also included (anti-β-actin; A-1978,
Sigma). Incubation with the primary antibodies was carried out overnight at 4 ◦C. The next day,
membranes were washed and incubated in TBS with the specific secondary antibodies coupled to HRP,
rabbit anti-mouse (1:1000 dilution; P0260, Dako) or goat anti-rabbit (1:1000 dilution; P0448, Dako),
or with streptavidin-HRP conjugate (1.5 µg/mL; SA10001, Thermo Fisher Scientific). Protein bands
were revealed using SuperSignalTM West Pico Plus chemiluminescent substrate (34580, Thermo
Fisher Scientific) to enhance signal, following the manufacturer’s protocol. Bands were visualized and
quantified using the Molecular Imager®Gel DocTM XR+ System with Image Lab software (Bio-Rad).
2.7. Immunofluorescence Microscopy
HUVECs were grown to confluence in 12 mm diameter coverslips, previously coated with 0.2%
gelatin (Sigma-Aldrich) in PBS. Cells were fixed with 3% paraformaldehyde in PBS and permeabilized
with 0.1% Triton X-100 during 10 min at room temperature. HUVECs were blocked with PBS containing
either 2% BSA (galectin-3) or 1% BSA plus 5% normal goat serum [NGS] (TRIM21). In order to monitor
the co-localization of endoglin with TRIM21 or galectin-3, samples were incubated first with the
mouse monoclonal antibody anti-human endoglin (P4A4; sc-20072, Santa Cruz Biotech). After washing
twice with PBS, samples were incubated with antibodies, anti-TRIM21 (rabbit mAb #92043, Cell
Signaling Technology) or anti-galectin-3 (rabbit polyclonal IgG, #PA5-34819, Thermo Fisher Scientific).
Then, after several washing steps with PBS, cells were incubated with the secondary antibodies Alexa
488 goat anti-mouse IgG or Alexa 647 goat anti-rabbit IgG. To visualize the samples and for nuclear
staining, slides were mounted in Prolong-DAPI (4′,6-diamidino-2-phenylindole) reagent (Molecular
Probes, Invitrogen). Samples were observed using a SP5 fluorescence confocal microscope (DMI6000
CS Leica Microsystems).
2.8. Bio-Layer Interferometry Measurements
Protein–protein interactions were measured by bio-layer interferometry using a single channel
BLItz system (ForteBio BLItz®). Recombinant human endoglin/CD105 protein (1097-EN-025, R&D) was
diluted to a final concentration of 250 µg/mL in PBS containing 0.1% BSA. Recombinant proteins tagged
with 6xHis were resuspended following the manufacturer´s recommendations. Human full-length
TRIM21 protein (RO52; 6His-tag, N-terminus, LSBio) was diluted to a final concentration of 250 µg/mL in
0.2 M Tris/pH 7.4 + 25% glycerol buffer. Human full-length galectin-3 protein tagged at the C-terminus
(LGALS3; 6His-tag, LS-G39216, LSBio) or the N-terminus (LS-G26359; 6His-tag, LSBio) were diluted in
distilled water or 10% glycerol in PBS/pH 7.4, respectively, to a final concentration of 100–200 µg/mL.
The 6His-tagged proteins (galectin-3 or TRIM21) were immobilized on Ni–NTA (Nickel-nitrilotriacetic
acid) biosensor tips and 4.1 µM soluble endoglin, or its corresponding control buffer was added to
the biosensor to measure the endoglin-TRIM21 or endoglin-galectin-3 binding. Each binding reaction
was carried out first with a 30 sec baseline (buffer), followed by a 300 s association phase (protein
binding) and a 300 s dissociation phase (buffer only). Assays were performed by duplicate, and binding
graphs were constructed by representing the experimental interferometry binding values (nm) and the
duration of experiment run (sec). BLItz Pro software was used to analyze the data.
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2.9. Statistical Analysis
All quantified results are shown as mean ± SD. Differences in mean values were analyzed using
Student´s t test. Asterisks indicate statistically significant values between selected conditions (*p < 0.05;
**p < 0.01; ***p < 0.005; ns not significant).
3. Results
3.1. Identification of Human Proteins Interacting with Endoglin Using Cell-Free Protein Microarray
Technology
Recombinant sEng, encompassing the extracellular domain of human endoglin, was probed
twice against a commercially available microarray that contains over 9000 unique human proteins
individually purified and arrayed (Microarray v5.0, Life Technologies). Among these, we identified
22 proteins common to both replicates, strongly interacting with endoglin (Table 1). The stringent list
of potential interactors was selected by imposing a Z-score ≥2.0 as a threshold.
Table 1. Human protein-array analysis of endoglin interactors1.
Accession # Protein Name Cellular Compartment
NM_172160.1 Potassium voltage-gated channel, shaker-related subfamily, beta
member 1 (KCNAB1), transcript variant 1 Plasma membraneQ14722
NM_138565.1 Cortactin (CTTN), transcript variant 2 Plasma membraneQ14247
BC036123.1 Stromal membrane-associated protein 1 (SMAP1) Plasma membraneQ8IYB5
NM_173822.1 Family with sequence similarity 126, member B (FAM126B) Plasma membrane, cytosol
Q8IXS8
BC047536.1 Sciellin (SCEL) Plasma membrane, extracellular or secreted
O95171
BC068068.1 Plasma membrane, mitochondrion, nucleus,
extracellular or secretedP17931 Galectin-3
BC001247.1 Actin-binding LIM protein 1 (ABLIM1) Cytoskeleton
O14639
NM_198943.1 Family with sequence similarity 39, member B (FAM39B) Endosome, cytoskeleton
Q6VEQ5
NM_005898.4 Cell cycle associated protein 1 (CAPRIN1), transcript variant 1 Cytosol
Q14444
BC002559.1 YTH domain family, member 2 (YTHDF2) Nucleus, cytosol
Q9Y5A9
NM_003141.2 Nucleus, cytosol
P19474
Tripartite motif-containing 21 (TRIM21)
BC025279.1 Scaffold attachment factor B2 (SAFB2) NucleusQ14151
BC031650.1 Putative E3 ubiquitin-protein ligase SH3RF2 NucleusQ8TEC5
BC034488.2 ATP-binding cassette, sub-family F (GCN20), member 1 (ABCF1) NucleusQ8NE71
BC040946.1 Spliceosome-associated protein CWC15 homolog (HSPC148) NucleusQ9P013
NM_003609.2 HIRA interacting protein 3 (HIRIP3) NucleusQ9BW71
NM_005572.1 Lamin A/C (LMNA), transcript variant 2 NucleusP02545
NM_006479.2 RAD51 associated protein 1 (RAD51AP1) NucleusQ96B01
NM_014321.2 Origin recognition complex, subunit 6 like (yeast) (ORC6L) NucleusQ9Y5N6
NM_015138.2 RNA polymerase-associated protein RTF1 homolog (RTF1) NucleusQ92541
NM_032141.1 Coiled-coil domain containing 55 (CCDC55), transcript variant 1 NucleusQ9H0G5
BC012289.1 Protein PRRC2B, KIAA0515 Data not availableQ5JSZ5
1 Microarrays containing over 9000 unique human proteins were screened using recombinant sEng as a probe. Protein
interactors showing the highest scores (Z-score ≥2.0) are listed. GeneBank (https://www.ncbi.nlm.nih.gov/genbank/)
and UniProtKB (https://www.uniprot.org/help/uniprotkb) accession numbers are indicated with a yellow or green
background, respectively. The cellular compartment of each protein was obtained from the UniProtKB webpage.
Proteins selected for further studies (TRIM21 and galectin-3) are indicated in bold type with blue background.
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Although the probe encoded the extracellular domain of endoglin, gene ontology analyses revealed
that the selected proteins were located in different subcellular compartments, including the cytoplasm,
nucleus, membrane, and extracellular subsets. Putative endoglin interactors included cytoskeletal
components, ion channels, soluble factors, ubiquitin-ligases, RNA polymerases, extracellular matrix
proteins, and membrane receptors, among others (Table 1). Among these, galectin-3 and TRIM21 were
selected for validation due their involvement in several biological functions shared by endoglin.
3.2. Galectin-3 Interacts with Endoglin in Cells
Galectin-3 is a secreted member of the lectin family with the capacity to bind membrane
glycoproteins like endoglin and is involved in the pathogenesis of many human diseases [52].
We confirmed the protein screen data for galectin-3, as evidenced by two-way co-immunoprecipitation
of endoglin and galectin-3 upon co-transfection in CHO-K1 cells. As shown in Figure 1A, galectin-3
and endoglin were efficiently transfected, as demonstrated by Western blot analysis in total cell extracts.
No background levels of endoglin were observed in control cells transfected with the empty vector (Ø).
By contrast, galectin-3 could be detected in all samples but, as expected, showed an increased signal in
cells transfected with the galectin-3 expression vector. Co-immunoprecipitation studies of these cell
lysates showed that galectin-3 was present in endoglin immunoprecipitates (Figure 1B). Conversely,
endoglin was also detected in galectin-3 immunoprecipitates (Figure 1C).
Next, we analyzed the interaction between galectin-3 and endoglin by biolayer interferometry [53,54]
as implemented in the BLItzTM instrument, which allows kinetic analysis of protein–protein interactions
using small amounts of protein. Galectin-3 with a 6His-tag at the C-terminus was immobilized
on Ni–NTA biosensor tips, protein interactions were measured against soluble endoglin or its
corresponding control buffer, and the association kinetics was monitored. As shown in Figure 1D,
a specific interaction between endoglin and galectin-3 is visualized as compared to the background
signal. Interestingly, similar experiments using galectin-3 with a 6His-tag at the N-terminus did not
display any specific interaction with endoglin (data not shown), suggesting that the N-terminus of
galectin-3 shelters the binding domain of endoglin.
The interaction and association results between galectin-3 and endoglin shown above, prompted us
to test whether galectin-3 co-localized with membrane-bound endoglin at the cellular level. Supporting
this hypothesis, co-localization of endogenous galectin-3 and endoglin in the plasma membrane of
HUVECs under basal conditions was observed by confocal microscopy (Figure 2).
Immunostaining of galectin-3 was detected at the membrane and intracellular compartments,
whereas endoglin signal was mainly located at the cell surface (Figure 2A). Some of these cells
showed a clear membrane co-localization of galectin-3 and endoglin, as depicted in the merged
images (Figure 2B, yellow staining). Because both endoglin and galectin-3 are expressed by endothelial
cells [28,52], their additional co-localization within the same secretory pathway (for example in the
Golgi) cannot be excluded. This would be compatible with the occasional perinuclear yellow staining
observed (Figure 2B). Control labeling in the absence of primary antibodies did not show any positive
signals (Supplementary Materials Figure S1), ruling out a potential artifact of immunofluorescent
secondary antibodies. Taken together, the above results demonstrate the interaction and association
between galectin-3 and endoglin.
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Figure 1. Protein–protein association between galectin-3 and endoglin. (A–C). Co-immunoprecipitation of
galectin-3 and endoglin. CHO-K1 cells were transiently transfected with pcEXV-Ø (Ø), pcEXV–HA–EngFL
(Eng) and pcDNA3.1–Gal-3 (Gal3) expression vectors. (A) Total cell lysates (TCL) were analyzed by
SDS-PAGE under reducing conditions, followed by Western blot (WB) analysis using specific antibodies to
endoglin, galectin-3 and β-actin (loading control). Cell lysates were subjected to immunoprecipitation (IP)
with anti-endoglin (B) or anti-galectin-3 (C) antibodies, followed by SDS-PAGE under reducing conditions
and WB analysis with anti-endoglin or anti-galectin-3 antibodies, as indicated. Negative controls with
an IgG2b (B) and IgG1 (C) were included. (D) Protein-protein interactions between galectin-3 and
endoglin using Bio-layer interferometry (BLItz). The Ni–NTA biosensors tips were loaded with 7.3 µM
recombinant human galectin-3/6xHis at the C-terminus (LGALS3), and protein binding was measured
against 0.1% BSA in PBS (negative control) or 4.1 µM soluble endoglin (sEng). Kinetic sensorgrams
were obtained using a single channel ForteBioBLItzTM instrument.
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Figure 2. Galectin-3 and endoglin co-localize in human endothelial cells. Human umbilical vein-derived
endothelial cell (HUVEC) monolayers were fixed with paraformaldehyde, permeabilized with
Triton X-100, incubated with the mouse mAb P4A4 anti-endoglin, washed, and incubated with
a rabbit polyclonal anti-galectin-3 antibody (PA5-34819). Galectin-3 and endoglin were detected by
immunofluorescence upon incubation with Alexa 647 goat anti-rabbit IgG (red staining) and Alexa
488 goat anti-mouse IgG (green staining) secondary antibodies, respectively. (A) Single staining of
galectin-3 (red) and endoglin (green) at the indicated magnifications. (B) Merge images plus DAPI
(nuclear staining in blue) show co-localization of galectin-3 and endoglin (yellow color). Representative
images of five different experiments are shown.
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3.3. TRIM21 Interacts with Endoglin in Cells
The TRIM family is a highly conserved group of E3 ubiquitin ligase proteins that have been
implicated in the regulation of the TGF-β-dependent cellular, as well as in the ubiquitination and
degradation of several components of TGF-β signaling pathway [55]. Unfortunately, little is known
about the connection between the TRIM family and the TGF-β auxiliary receptor endoglin of endothelial
cells. Among TRIM family members, TRIM21 acts not only as an E3 ubiquitin ligase on different target
proteins, but also as a substrate in auto-ubiquitination, both leading to protein degradation [56–58].
In addition, TRIM21 is involved in cancer [59,60], inflammation [61–64], intracellular immunity,
and autoimmunity [47,65–67]. Here, we validated the protein screen data for TRIM21, using two-way
co-immunoprecipitation analysis of endoglin and TRIM21 in HUVECs and co-transfected CHO-K1
cells (Figure 3).
Endoglin and TRIM21 were readily detected in whole HUVECs lysates, as shown by WB analysis
(Figure 3A). Co-immunoprecipitation studies of these lysates showed that endoglin was present in
TRIM21 immunoprecipitates, but not in a negative control (Figure 3B). In our hands, TRIM21 could
not be detected in endoglin immunoprecipitates from HUVECs (data not shown). For this reason,
a proteomic approach was used. Thus, HUVEC lysates were subjected to immunoprecipitation with
anti-endoglin antibodies, and the total proteins associated with immunoprecipitates were separated by
SDS-PAGE, followed by trypsin digestion and proteomic analysis by mass spectrometry. As shown
in Supplementary Materials Table S1, TRIM21 was found among the putative endoglin-interacting
proteins identified by this technique. Further support for the endoglin/TRIM21 association was
obtained from co-transfection experiments in CHO-K1 cells (Figure 3C,D). Figure 3C shows that
endoglin and TRIM21 were clearly expressed upon transfection of CHO-K1 cells, as evidenced by
WB analysis of total cell extracts. Co-immunoprecipitation studies of these cell lysates showed
that endoglin was present in TRIM21 immunoprecipitates (Figure 3D, upper panel). Conversely,
TRIM21 was detected in endoglin immunoprecipitates, as shown by WB analysis (Figure 3D, lower
panel). In addition, co-immunoprecipitation studies of CHO-K1 cells, previously co-transfected with
TRIM21 and two different truncated constructs (pDisplay–HA–EngEC and pDisplay–HA–EngTMEC),
both devoid of the cytoplasmic tail of endoglin, revealed that these mutant proteins were present in
TRIM21 immunoprecipitates, suggesting that the cytoplasmic domain of endoglin is not required for
interaction with TRIM21 (Figure 3E).
Further evidence for the interaction between TRIM21 and endoglin was obtained by biolayer
interferometry. The 6His-tagged TRIM21 was immobilized on Ni–NTA biosensor tips, and protein
interactions were measured against soluble endoglin or its corresponding control buffer (Figure 3F).
The association kinetics was monitored, revealing a specific interaction between TRIM21 and endoglin,
as compared to the background signal of BSA.
Next, we tested whether TRIM21 co-localized with membrane-bound endoglin at the cellular
level. As shown by confocal microscopy, immunostaining of TRIM21 was detected at the nucleus,
membrane, and cytosolic compartments, whereas endoglin signal was mainly located at the cell surface
(Figure 4). Endogenous TRIM21 and endoglin co-localized in the plasma membrane of HUVECs under
basal conditions (Figure 4A). As depicted in the merged images (Figure 4B, yellow staining), some cells
showed a clear membrane and perinuclear co-localization of TRIM21 and endoglin. Control labeling in
the absence of primary antibodies did not show any positive signal (Figure S1), ruling out a potential
artifact of immunofluorescent secondary antibodies.
Taken together, the above results demonstrate for the first time the interaction and association
between TRIM21 and endoglin.
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Figure 3. Protein–protein association between TRIM21 and endoglin. (A–E) Co-immunoprecipitation
of TRIM21 and endoglin. A,B. HUVEC monolayers were lysed and total cell lysates (TCL) were
subjected to SDS-PAGE under reducing (for TRIM21 detection) or nonreducing (for endoglin
detection) conditions, followed by Western blot (WB) analysis using antibodies to endoglin, TRIM21
or β-actin (A). HUVECs lysates were subjected to immunoprecipitation (IP) with anti-TRIM21
or negative control antibodies, followed by WB analysis with anti-endoglin (B). C,D. CHO-K1
cells were transiently transfected with pDisplay–HA–Mock (Ø), pDisplay–HA–EngFL (E) or
pcDNA3.1–HA–hTRIM21 (T) expression vectors, as indicated. Total cell lysates (TCL) were subjected
to SDS-PAGE under nonreducing conditions and WB analysis using specific antibodies to endoglin,
TRIM21, and β-actin (C). Cell lysates were subjected to immunoprecipitation (IP) with anti-TRIM21
or anti-endoglin antibodies, followed by SDS-PAGE under reducing (upper panel) or nonreducing
(lower panel) conditions and WB analysis with anti-TRIM21 or anti-endoglin antibodies. Negative
controls of appropriate IgG were included (D). E. CHO-K1 cells were transiently transfected
with pcDNA3.1–HA–hTRIM21 and pDisplay–HA–Mock (Ø), pDisplay–HA–EngFL (FL; full-length),
pDisplay–HA–EngEC (EC; cytoplasmic-less) or pDisplay–HA–EngTMEC (TMEC; cytoplasmic-less)
expression vectors, as indicated. Cell lysates were subjected to immunoprecipitation with anti-TRIM21,
followed by SDS-PAGE under reducing conditions and WB analysis with anti-endoglin antibodies,
as indicated. The asterisk indicates the presence of a nonspecific band. Mr, molecular reference; Eng,
endoglin; TRIM, TRIM21. (F) Protein–protein interactions between TRIM21 and endoglin using
Bio-layer interferometry (BLItz). The Ni–NTA biosensors tips were loaded with 5.4 µM recombinant
human TRIM21/6xHis at the N-terminus (R052), and protein binding was measured against 0.1% BSA
in PBS (negative control) or 4.1 µM soluble endoglin (sEng). Kinetic sensorgrams were obtained using a
single channel ForteBioBLItzTM instrument.
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Figure 4. TRIM21 and endoglin co-localize in human endothelial cells. HUVEC monolayers were
fixed with paraformaldehyde, permeabilized with Triton X-100, incubated with the mouse mAb
P4A4 anti-endoglin, washed and incubated with a rabbit monoclonal anti-TRIM21 antibody (#92043).
TRIM21 and endoglin were detected by immunofluorescence upon incubation with Alexa 647 goat
anti-rabbit IgG (red staining) and Alexa 488 goat anti-mouse IgG (green staining) secondary antibodies,
respectively. (A) Single staining of TRIM21 (red) and endoglin (green) at the indicated magnifications.
(B) Merge images plus DAPI (nuclear staining in blue) show co-localization of TRIM21 and endoglin
(yellow color). Representative images of four different experiments are shown.
4. Discussion
The protein array screening allowed us to test a total of >9000 putative interactions with the
extracellular region of endoglin using commercially available sEng. This is at variance with other
screening studies which have previously used either the cytoplasmic region of endoglin or the full- length
protein as a bait [9,68–71]. Here, we identified 22 interactors that passed our stringent criteria. They are
located in different subcellular compartments, including plasma membrane, cytosol, cytoskeleton or
extracellular secreted proteins. Surprisingly, some of the identified interactors are not membrane or
secreted proteins, something that would be expected from the extracellular region of a type I membrane
protein as endoglin. Several interactors are located in the nucleus, suggesting a yet-to-discover function
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for endoglin. Compatible with this hypothesis, endoglin deficiency or overexpression in human cells
can regulate the expression of a wide range of target genes at the transcriptional level [72–74]. While the
localization of endoglin in the nucleus has not been demonstrated, the intriguing functional impact of
endoglin interactions with the newly identified nuclear partners remains to be explored.
Here we have confirmed the interaction between endoglin and two previously unrecognized
partners, galectin-3 and TRIM21. Endoglin is a glycoprotein with several consensus N- and O-
linked glycosylation sites [28]. Therefore, its capacity to bind galectin-3 fully agrees with the fact
that this lectin contains a carbohydrate-recognition-binding domain involved in the interaction with
different membrane glycoproteins [52]. Given the key role of endoglin in the vascular system, one of
the reasons for choosing galectin-3 was its widely reported involvement in cardiovascular disease,
including cardiac fibrosis and inflammation, pathological angiogenesis, aortic stenosis, abdominal aortic
aneurysm, endothelial dysfunction, cardiovascular remodeling or hypertension [75–80]. Interestingly,
both galectin-3 and endoglin can be expressed as a secreted biomarker in circulation and both
have been involved in endothelial dysfunction and inflammation. Galectin-3 has been reported to
exacerbate endothelial dysfunction via oxidized-LDL [79] and likely through oxidized-HDL-induced
LOX-1 activation [81]. Further, sEng synergizes with hypercholesterolemia to aggravate endothelial
and vessel wall dysfunction [26]. Interestingly, galectin-3 and sEng are increased in preeclampsia
a systemic syndrome associated with inflammation, endothelial dysfunction and anti-angiogenic
activity [18,43,82]. Additionally, galectin-3 and sEng regulate endothelial cell migration and
angiogenic activity [22,83–86]. Because abnormal levels of galectin-3 and sEng are found in several
endothelium-related pathological conditions, these results suggest that these soluble proteins may
associate with each other, acting in concert to regulate endothelial function in vascular-related
pathologies. In this regard, the galectin-3/endoglin interaction in the endothelial context is supported
by a recent and preliminary work where endoglin was identified, among other glycoproteins, after
a purification process of HUVEC extracts through a galectin-3 affinity column [86]. In addition,
galectin-3 was detected in endoglin immunoprecipitates from lysates of HUVECs previously treated
with recombinant galectin-3 [87]. Galectin-3 is a relatively abundant component of the tumor
microenvironment, where it has been found to regulate critical aspects of cancer biology, such
as metastasis, apoptosis, and immune surveillance [88]. Since elevated levels of sEng are also found
in different types of cancer [9,89], it is tempting to speculate on the involvement of sEng/galectin-3
interaction in tumor progression and metastasis.
We have also shown that endoglin can interact with TRIM21, a protein involved in multiple
cell functions. As other members of the TRIM family, TRIM21 can act as a ubiquitination enzyme
targeting for degradation different proteins [56–58,90]. The TRIM family has been shown to ubiquitinate
different components of the TGF-β signaling pathway [55,91], and our results suggest for the first
time that TRIM21 may target for degradation the TGF-β auxiliary receptor endoglin. This interesting
line of research should be explored in future experiments and may be key to understanding the
described long half-life of this relatively stable glycoprotein [92]. Several reports have shown the
involvement of TRIM21 in cancer development [58–60,93], a characteristic shared by other TRIM
family members [55] and, interestingly, by endoglin [9,89]. TRIM21 functions as a tumor suppressor
in breast cancer and high expression levels of TRIM21 are associated with longer overall survival of
breast cancer patients [58,60]. Notably, a similar role for endoglin as a tumor suppressor in breast,
prostate, esophageal, and skin carcinomas has been described [13–16]. These data suggest that, upon
interacting with each other, endoglin and TRIM21 may act in concert to regulate cancer development.
In line with this, both TRIM21 [58] and endoglin [94] appear to induce the epithelial–mesenchymal
transition (EMT), a key process in cancer development. In addition, galectin-3 can also induce the
mesenchymal transition of endothelial cells [95]. Another interesting finding of our studies is the
presence of TRIM21 in endothelial cells, considering that the expression and function of TRIM21 in
this cell lineage has been poorly addressed so far. Very recently, it has been reported that TRIM21
from human lung endothelial cells displays a modulatory role during the inflammatory response to
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lipopolysaccharide (LPS), suggesting that TRIM21 is a potential therapeutic target in sepsis-induced
endothelial dysfunction [96,97]. Similarly, endothelial endoglin, which is markedly increased during
inflammation [2,98], regulates several inflammation-related processes such as LPS-induced leukocyte
extravasation [24] or cell-mediated vascular repair [99]. In addition, patients with septic shock present
higher levels of circulating sEng compared to healthy individuals [100], while it has been reported that
sEng contributes to endothelial dysfunction in animal models [26,27]. Further studies are needed to
elucidate the exact role that the TRIM21/endoglin interaction plays in the complex role of endothelial
cells during the inflammatory process.
5. Conclusions
In summary, here we identified more than twenty novel interactors of the extracellular region of
endoglin, of which endoglin/galectin-3 and endoglin/TRIM21 associations were further characterized.
Given the key involvement of membrane-bound and soluble endoglin in different pathophysiological
contexts, these findings open up a new research avenue to better understand the mechanism of action
of endoglin. Future independent studies remain to be performed to assess the functional significance
of the endoglin interactions with these novel partners.
Supplementary Materials: The following is available online at http://www.mdpi.com/2073-4409/8/9/1082/s1,
Figure S1: Immunofluorescence staining of galectin-3, TRIM21, and endoglin in human endothelial cells, Table S1:
Proteomic analysis of endoglin-associated proteins.
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